Ventures - Digital Health Opportunities
Highlights from Cleveland Clinic Innovations Innovation
We welcome potential partners to learn more about our new companies featuring next-generation medical products.
Cleveland Clinic Innovations' goal is to support venture-stage companies in their efforts to commercialize Cleveland Clinic intellectual property and positively impact patient care. Our diverse portfolio of more than 40 spinoff companies showcases our mission to make the latest scientific discoveries and inventions available to patients around the world. A dedicated team of business experts supports our ventures throughout their life cycle, from formation, management and governance to funding and potential acquisition. Startup companies can access our state-of-the-art technology Incubator, as well as the Cleveland Clinic and Lerner Research Institute’s vast resources for research and testing.
Companies Currently Fundraising
Floreo
Stage: Actively Raising Series B
Floreo is a virtual reality therapy modality to enable immersive/experiential learning to accommodate and support individuals with diverse neurological profiles. The learner follows clinician-designed lessons and guidance to build social, communication, behavioral, emotional regulation, safety and adaptative life skills. Digital delivery and personalized interventions supplement the in-clinic standard of care , increasing accessibility and flexibility for learners.
-1.png "Untitled design (10)-1")
Avaneer Health
Stage: Actively Raising Series B
Avaneer Health was founded by leaders with the vision to transform how healthcare shares information via a unique, interoperable network designed by and for healthcare. Avaneer streamlines healthcare administration where health information can be shared in real-time, with permission, and in control of the owner or steward of the data, leveraging collaboration services for identity, workflow, zero trust security, and solution marketplace.
Healthcare Navigation Solutions
Stage: Actively Raising Series A
CancerNAV automates and standardizes the cancer patient navigation process across the continuum of care. CancerNAV supports clinical and non-clinical patient navigation through workflow tracking and documentation of care coordination. Not only is CancerNAV a robust solution, but it is also intuitive, user-friendly, requires little training and education, and can be implemented in as little as 90 days.
.png "Untitled design (9)")
Ceraxis Health
Stage: Actively Raising Seed
Ceraxis Health has developed a platform for longitudinal tracking of symptoms and management to address patient functional health, quality of life outcomes and treatment planning and monitoring through real-time, data-driven care management for neurological conditions such as Parkinson’s Disease.
Qr8 Health
Stage: Actively Raising Series A
Qr8 Health is a digital health company providing standardized, validated, patient-self-administered assessments for the measurement of neurological and motor function along with patient-reported outcomes administered on a mobile tablet device and easily integrated into electronic health records. Founded in 2016, the company has developed applications enabling transformational improvement in patient care by providing medical solutions for collecting highly standardized clinical data and patient-reported outcomes, in any medical or home setting.
.jpg "sports-data-GettyImages-1527345935 (1)")
Sports Data Labs
Stage: Actively Raising Series A
Sports Data Labs, Inc. (SDL) is a venture-backed, award-winning leader in the collection, analysis, and distribution of real-time human data from on-body sensors and other data sources. SDL provides patented and proprietary technologies that enable individuals to collect, control, and distribute their personal data, using artificial intelligence to transform this data into metrics, insights, and predictions for various real-time and on-demand applications. SDL also offers data acquisition and monetization solutions for buyers and sellers of personal data.
.png "Untitled design (8)")
Mobius Care
Stage: Actively Raising Series A
Mobius is personalizing Inflammatory Bowel Disease (IBD) therapeutic and diagnostic care, through its proprietary AI tool, applied to targeting host and microbiome pathways that infect gastrointestinal (GI) tract wounds. The Company’s technology can also identify subsets of patients who are likely to respond favorably to an existing arsenal of well-characterized drug candidates. Additionally, Mobius is developing therapeutics to treat the dysfunctional wound healing and dysfunctional microbiome associated with IBD.
Method AI
Stage: Actively Raising Series A
Method AI is developing a surgical navigation platform to drive improved patient outcomes for robotic oncology procedures. The company’s product will leverage deep tissue imaging and machine learning algorithms to provide physicians with real-time guidance against an AI-generated surgical plan.
